first
clinic
evalu
adenoviru
ad
base
vector
gene
therapi
initi
led
great
anticip
futur
util
howev
excit
surround
gene
therapi
particularli
adbas
therapi
diminish
upon
death
jess
gelsing
recent
discourag
result
hiv
vaccin
step
trial
brought
efficaci
safeti
issu
forefront
even
ad
vector
still
consid
among
safest
effect
vaccin
vector
innat
preexist
immun
ad
mediat
much
acut
toxic
reduc
therapeut
efficaci
observ
follow
vaccin
vector
thu
innov
strategi
must
continu
develop
reduc
adspecif
antigen
immun
recognit
review
provid
overview
critiqu
promis
strategi
includ
result
preclin
trial
mice
nonhuman
primat
aim
reviv
futur
adbas
vaccin
vector
encod
diseasespecif
epitop
use
vaccin
approach
wide
rang
infecti
diseas
includ
malaria
ebola
sar
pseudomona
hiv
infect
sever
featur
ad
make
ideal
vector
system
mucos
deliveri
encod
transgen
includ
low
pathogen
rel
safeti
profil
larg
transgen
capac
high
transgen
express
eas
manipul
adbas
vaccin
particularli
effect
high
antigenspecif
immun
respons
induc
encod
transgen
provid
prophylact
therapeut
protect
transmit
diseas
cancer
howev
activ
innat
immun
respons
presenc
preexist
immun
pei
common
ad
vector
infect
human
popul
increas
potenti
toxic
limit
efficaci
vaccin
current
identifi
serotyp
ad
human
ad
serotyp
extens
investig
gene
therapi
vector
ad
compos
dna
core
surround
nonenvelop
icosahedr
protein
capsid
capsid
compos
structur
trimer
hexon
protein
pentamer
penton
base
protein
trimer
fiber
protein
extend
viru
cap
globular
knob
domain
highaffin
bind
knob
domain
coxsacki
viru
ad
receptor
car
express
surfac
mani
cell
allow
vector
interact
integrin
v
v
rgd
peptid
penton
base
integrin
bind
mediat
vector
endocytosi
via
clathrinco
pit
acidif
endosom
induc
vector
uncoat
endosomalysi
releas
viral
capsid
transport
microtubul
nucleu
dock
nuclear
uptak
nuclear
pore
complex
dosedepend
innat
immun
reaction
capsid
ad
vector
involv
activ
andor
recruit
kupffer
cell
endotheli
cell
neutrophil
splenic
macrophag
dendrit
cell
dc
concomit
product
proinflammatori
cytokin
chemokin
appear
mainli
respons
induc
associ
acut
potenti
lethal
toxic
well
diminish
therapeut
target
follow
system
administr
howev
becom
appar
nonimmun
cell
transduc
ad
vector
bind
car
v
integrin
also
respond
ad
increas
product
inflammatori
cytokin
chemokin
overwhelm
acut
toxic
gener
respons
high
dose
ad
vector
believ
respons
death
jess
gelsing
bind
ad
vector
complement
pathogenrecognit
receptor
erythrocyt
blood
factor
implic
facilit
innat
immun
respons
opson
complement
mediat
extens
transduct
liver
cell
may
involv
ad
bind
neutrophil
kupffer
cell
platelet
lead
inflammatori
cytokin
chemokin
product
possibl
thrombocytopenia
transduc
hepatocyt
via
cardepend
bind
bind
coagul
factor
ix
factor
x
also
mediat
hepatocyt
transduct
vivo
even
vector
unabl
bind
car
factor
vii
protein
c
also
interact
ad
mediat
hepatocyt
transduct
vitro
transduct
mediat
coagul
factor
occur
bind
heparan
sulfat
proteoglycan
lipoprotein
receptorrel
protein
sever
recent
report
implic
scaveng
receptor
primari
mean
kupffer
cell
recogn
clear
ad
vector
scaveng
receptorbind
neg
charg
ad
capsid
appear
mediat
uptak
kupffer
cell
although
opson
complement
igm
may
also
involv
note
contrast
previou
report
xu
et
al
recent
report
coagul
factor
requir
deliveri
ad
kupffer
cell
deplet
coagul
factor
actual
enhanc
kupffer
cell
uptak
diminish
transduct
hepatocyt
therefor
differ
method
may
requir
prevent
transduct
hepatocyt
versu
uptak
kupffer
cell
previous
thought
prevent
bacteri
infect
found
bind
ad
vitro
prevent
endosomalysi
step
requir
ad
uncoat
product
transduct
cell
addit
liver
sequestr
vector
potenti
induct
acut
toxic
innat
immun
respons
ad
lead
product
adapt
immun
respons
inde
pei
ad
pei
may
found
american
popul
popul
countri
ad
pei
limit
effect
adbas
vaccin
sinc
adspecif
cell
gener
upon
exposur
viru
surpris
memori
cell
detect
major
human
import
gener
vaccin
immun
inflammatori
cytokin
releas
upon
ad
administr
contribut
gener
tcell
respons
cell
express
protein
deriv
ad
vector
andor
transgen
howev
tcellmedi
ad
pei
shown
diminish
tcell
respons
transgen
product
follow
cellular
transduct
ad
capsid
peptid
peptid
transgen
product
present
cell
via
mhci
molecul
surfac
transduc
cell
addit
dc
endocytos
ad
indirectli
scaveng
apoptot
debri
transduc
cell
directli
nonspecif
macropinocytosi
target
receptormedi
uptak
present
vectorencod
peptid
cell
via
mhci
ii
molecul
therebi
activ
cell
furthermor
dc
activ
ad
possibl
ad
genom
interact
nacht
domain
leucinerich
repeat
pydcontain
protein
nalp
tolllik
receptor
tlr
promot
tcell
respons
peptid
deriv
ad
vector
gene
transgen
cell
provid
help
bcell
matur
isotyp
switch
cell
provid
help
develop
expans
cytotox
cell
thu
transduc
dc
gener
cytotox
cell
capabl
elimin
transduc
cell
express
ad
gene
transgeneproduct
peptid
clearli
benefici
context
mount
effect
respons
diseasespecif
transgen
product
order
combat
intracellular
pathogen
tumor
howev
cytotox
cell
gener
ad
vector
protein
elimin
transduc
cell
express
ad
gene
well
transgen
result
diminish
immunotherapeut
gene
express
adspecif
effector
memori
cell
quickli
activ
follow
ad
vector
administr
capsid
protein
hexon
appear
major
target
cell
although
cell
also
detect
ad
earli
protein
addit
sever
epitop
recogn
cell
conserv
among
ad
serotyp
includ
ad
tropic
speci
importantli
region
ad
normal
downregul
mhci
express
infect
cell
ad
delet
increas
transgen
payload
size
may
actual
enhanc
recognit
adtransduc
cell
cytotox
cell
cell
specif
earli
gene
could
elimin
adinfect
cell
product
encod
transgen
underway
rehighlight
result
recent
antihiv
vaccin
step
trial
tcellmedi
ad
pei
hinder
effect
vaccin
may
even
result
increas
suscept
infect
enhanc
vectorrel
toxic
addit
adspecif
cell
adspecif
neutral
antibodi
nab
predomin
direct
hexon
fiber
penton
base
gener
follow
first
exposur
ad
whether
natur
occur
one
immun
ad
vector
nab
inhibit
ad
transduct
cell
varieti
method
includ
prevent
cell
attach
facilit
viru
aggreg
clearanc
addit
antihexon
nab
allow
viru
entri
prevent
viru
gene
express
identifi
one
monoclon
antihexon
antibodi
character
shown
prevent
nuclear
entri
block
microtubuledepend
intracellular
transport
viru
follow
endosom
escap
nab
gener
hexon
hypervari
region
hvr
account
antiad
nab
appear
critic
viru
clearanc
significantli
limit
immunotherapeut
express
gene
deliv
ad
vector
therefor
method
prevent
induct
antiad
immun
allow
ad
vector
evad
pei
includ
adspecif
cell
nab
critic
advanc
effect
adbas
gene
therapi
varieti
method
shown
great
promis
review
primarili
focu
recent
advanc
effect
techniqu
avoid
acut
toxic
adapt
immun
respons
particular
report
method
specif
evalu
presenc
ad
pei
discuss
critic
initi
investig
show
immunosuppress
drug
enhanc
transgen
express
ad
vector
prevent
develop
antibodyand
tcellmedi
immun
ad
studi
open
door
develop
immuneevas
techniqu
clinic
util
immunosuppress
drug
prevent
antiad
immun
respons
question
owe
safeti
concern
mani
pathway
involv
initi
phase
acut
antiad
immun
respons
elucid
howev
pathway
highli
redund
thu
blockad
one
pathway
unlik
provid
complet
protect
antiad
immun
toxic
therefor
continu
evalu
method
circumv
antiad
immun
requir
follow
previou
report
suggest
pretreat
mice
antiinflammatori
glucocorticoid
prevent
adinduc
activ
innat
adapt
immun
respons
allow
effect
readministr
vector
seregin
et
al
report
pretreat
mice
dexamethason
dex
prevent
innat
immun
respons
vector
diminish
antiad
adapt
respons
specif
pretreat
dex
prevent
releas
inflammatori
cytokineschemokin
thrombocytopenia
inflammatori
gene
express
leukocyt
infiltr
liver
dex
treatment
protect
kupffer
cell
loss
follow
ad
inject
howev
interestingli
increas
level
ad
vector
genom
detect
liver
cell
earli
time
point
postinject
translat
higher
level
transgen
express
anticip
follow
blunt
acut
immun
respons
vector
adapt
immun
respons
also
alter
mice
receiv
dex
gener
ad
capsidspecif
primari
antibodi
reduc
respons
significantli
diminish
well
suggest
usual
tcellmedi
clearanc
cell
express
ad
vectorderiv
peptid
may
reduc
turn
may
lead
higher
transgen
express
level
addit
adspecif
nab
significantli
reduc
transgen
productspecif
lacz
igm
iga
antibodi
reduc
dextreat
mice
rel
concentr
transgen
productspecif
igg
antibodi
unchang
slight
reduct
ratio
respons
transgen
product
determin
antibodi
isotyp
preval
observ
suggest
potenti
vaccineinduc
immun
would
compromis
overal
result
suggest
pretreat
antiinflammatori
glucocorticoid
may
provid
protect
ad
vectorinduc
toxic
gener
adspecif
nab
naiv
anim
preserv
potenti
immun
respons
transgen
product
previou
report
also
demonstr
enhanc
transgen
product
express
follow
ad
administr
vivo
thu
seem
clear
pretreat
dex
provid
import
benefit
regard
safeti
system
administ
adbas
vaccin
may
improv
transgen
express
although
overal
efficaci
treatment
must
also
examin
anim
ad
pei
addeliv
transgen
consid
effici
incorpor
genom
host
cell
thu
admedi
gene
express
diminish
time
even
absenc
ad
pei
therefor
repeat
administr
ad
vector
necessari
effect
treatment
mani
diseas
regard
primeboost
vaccin
strategi
often
use
amplifi
effect
number
cell
requir
initi
rapid
respons
encod
antigen
howev
ad
pei
limit
induct
transgen
productspecif
immun
respons
achiev
follow
boost
anim
model
therefor
major
human
alreadi
ad
pei
imper
method
pei
evas
develop
institut
futur
util
success
adbas
vaccin
strategi
overcom
potenti
limit
adbas
vaccin
human
ad
pei
altern
serotyp
belong
differ
subgroup
investig
abil
avoid
acut
toxic
evad
antiad
immun
clearanc
nab
gener
uniqu
ad
serotyp
gener
specif
crossreact
serotyp
howev
mani
serotyp
afford
benefit
unabl
induc
high
transgen
express
less
amen
largescal
product
although
initi
problemat
novel
strategi
overcom
obstacl
show
promis
exampl
complement
cell
line
use
propag
high
titer
vector
although
transgen
productspecif
immun
respons
induc
vector
unaffect
pei
higher
vector
dose
requir
achiev
respons
compar
gener
vector
naiv
mice
may
prove
less
benefici
immunotherapi
ad
serotyp
vari
greatli
fiber
domain
carmedi
transduct
liver
cell
reduc
vector
chimer
vector
express
fiber
shaft
domain
serotyp
examin
abil
reduc
liver
transduct
vivo
hepatocyt
transduct
inflammatori
cytokin
chemokin
product
acut
liver
toxic
mice
significantli
diminish
follow
administr
vector
engin
express
knob
fiber
interestingli
appear
depend
length
shaft
domain
rather
abil
knob
directli
bind
car
per
se
sinc
vector
express
knob
shaft
domain
carbind
serotyp
short
shaft
also
reduc
acut
liver
toxic
diminish
toxic
presum
due
combin
factor
result
shorten
shaft
domain
includ
reduc
access
receptor
bind
well
inabl
bind
blood
factor
similar
decreas
product
inflammatori
cytokin
chemokin
observ
chimer
vector
express
long
short
fiber
lack
heatshock
proteininteract
domain
note
acut
product
inflammatori
cytokin
chemokin
reduc
adapt
immun
respons
gener
vector
similar
gener
unmodifi
vector
delet
rgd
motif
vector
reduc
hepatocyt
transduct
inflammatori
respons
even
vector
also
induc
antiad
adapt
respons
compar
unmodifi
develop
vector
base
ad
normal
infect
nonhuman
speci
may
also
provid
promis
solut
inde
chimpanze
ad
adc
gain
popular
sinc
initi
demonstr
human
serum
significantli
neutral
adc
vector
unlik
altern
human
serotyp
examin
version
easili
propag
vector
express
sarscoronaviru
antigen
elicit
higher
tand
bcell
respons
vector
mice
pei
mice
pei
singl
inject
encod
ebola
glycoprotein
provid
protect
lethal
challeng
unlik
correspond
vector
although
pei
impact
protect
confer
vector
slightli
reduc
antiebola
tand
bcell
respons
similar
decreas
immun
respons
observ
immun
vector
express
hiv
gag
result
suggest
although
tand
bcell
respons
gener
transgen
product
encod
adc
vector
may
less
robust
presenc
pei
may
still
suffici
effect
therapi
recent
report
examin
protect
effect
singledos
vaccin
three
differ
adc
vector
encod
fusion
protein
tand
bcell
epitop
malaria
mice
without
pei
vector
induc
greater
antigenspecif
tcell
respons
either
vector
differ
intramuscular
intraderm
inject
presenc
pei
protect
induc
adbas
vector
reduc
immun
offer
protect
offer
best
protect
mice
compar
without
pei
studi
group
show
immun
respons
protect
confer
could
increas
ad
full
intron
sequenc
human
cytomelagoviru
promot
use
drive
antigen
express
howev
author
also
point
fact
pei
detect
african
popul
pei
reduc
efficaci
vector
furthermor
ad
vector
like
pei
induc
exposur
initi
vaccin
may
affect
efficaci
subsequ
vector
immun
natur
respons
respect
impact
neutral
durat
transgen
product
express
remain
investig
especi
import
note
sever
ad
epitop
recogn
cell
conserv
among
broad
array
human
nonhuman
primatederiv
ad
make
like
cell
patient
pei
also
recogn
vector
deriv
virus
bovin
infecti
ad
examin
sinc
nab
bovin
report
human
popul
mous
model
singledos
inject
vector
encod
hemagglutinin
ha
antigen
influenza
induc
greater
level
cellular
immun
vector
diminish
pei
importantli
mice
pei
receiv
primeboost
regimen
vector
encod
ha
fulli
protect
lethal
influenza
viru
challeng
receiv
homolog
regimen
vector
thu
ad
vector
normal
infect
speci
human
may
induc
immun
respons
offer
protect
compar
superior
maintain
protect
even
presenc
pei
highlight
kobing
et
al
vector
capabl
afford
complet
protect
one
dose
without
need
addit
boost
critic
treat
diseas
requir
rapid
intervent
thu
worth
examin
potenti
merit
vector
base
ad
vector
specif
tropism
speci
canin
porcin
chicken
howev
opson
antibodi
reactiv
memori
cell
specif
canin
detect
human
indic
may
simpl
solut
evad
ad
pei
studi
also
emphas
differ
viral
vector
affect
qualiti
immun
respons
antigen
respons
must
thoroughli
investig
context
human
immun
predict
efficaci
vaccin
human
case
primeboost
strategi
remain
necessari
complet
protect
diseas
regress
immun
gener
prime
vector
dictat
need
use
altern
vector
prime
therefor
continu
valid
altern
serotyp
chimer
vector
critic
defin
avail
repertoir
vector
may
use
primeboost
immun
anoth
consider
must
rais
sinc
ad
vector
may
activ
tlr
influenc
innat
immun
respons
vector
transgen
product
differ
ad
serotyp
appear
induc
phenotyp
qualit
differ
immun
respons
transgen
product
observ
consist
notion
differenti
interact
tlr
may
contribut
phenomenon
yet
confirm
previou
studi
investig
effect
prime
antigen
form
either
plasmid
protein
follow
ad
vectorinduc
boost
shown
magnitud
qualiti
tcell
respons
significantli
influenc
form
prime
vaccin
similarli
prime
ad
vector
differ
serotyp
may
significantli
alter
humor
cellular
respons
transgeneencod
vaccin
recent
studi
compar
heterolog
primeboost
regimen
homolog
regimen
barouch
group
found
simian
immunodefici
viru
siv
gagspecif
respons
gener
rhesu
monkey
heterolog
primeboost
immun
greater
compar
homolog
primeboost
immun
vector
addit
boost
humor
cellular
respons
heterolog
vector
administr
increas
number
gagspecif
epitop
recogn
cell
nearli
four
time
primeboost
immun
vector
produc
enhanc
gagspecif
immun
respons
vaccin
attain
magnitud
gener
strategi
schirmbeck
et
al
demonstr
naiv
mice
adspecif
tcell
respons
gener
singl
inject
ad
vaccin
profoundli
influenc
divers
antigenspecif
tcell
respons
contrast
respons
follow
singl
immun
antigen
encod
dnabas
vaccin
plasmid
dnaencod
transgen
ad
vectorencod
antigen
unabl
gener
tcell
respons
subdomin
epitop
antigen
thu
effici
adand
transgen
productderiv
peptid
present
follow
transduct
dictat
kinet
develop
epitopespecif
tcell
respons
suggest
subdomin
epitop
effect
present
time
take
induc
adspecif
cytotox
tcell
respons
may
explain
observ
select
increas
transgen
productspecif
immun
respons
adspecif
tcell
respons
observ
dex
administ
conjunct
ad
vaccin
support
use
temporari
immun
suppress
enhanc
ad
vectorbas
vaccin
recent
result
also
document
profound
ad
speciesrel
differ
abil
stimul
secret
cytokin
human
plasmacytoid
dc
pdc
import
part
innat
immun
system
interestingli
studi
show
human
demonstr
stimulatori
effect
human
pdc
thu
combin
ad
vector
seroor
speciestyp
plasmid
dna
protein
antigen
use
primeboost
strategi
may
provid
differ
adjuv
signal
could
use
optim
combin
tailor
achiev
protect
immun
particular
pathogen
discoveri
major
nab
direct
ad
hexon
hvr
confirm
hvr
could
engin
incorpor
foreign
peptid
provid
rational
develop
chimer
vector
express
hvr
serotyp
chimer
vector
express
hvr
induc
significantli
greater
immun
respons
transgen
product
unmodifi
vector
mice
rhesu
monkey
pei
chimer
vector
seven
hvr
exchang
induc
level
antiantigen
immun
respons
mice
pei
naiv
mice
howev
replac
one
hvr
provid
littl
improv
nonchimer
vector
antigenspecif
immun
respons
induc
vector
greater
induc
immun
vector
confirm
initi
hypothesi
chimer
vector
would
retain
immunegener
capac
vector
hexon
hvr
also
found
major
bind
site
factor
x
possibl
factor
ix
bind
affin
factor
x
vari
serotyp
may
explain
differ
hepatocyt
transduct
vivo
previous
observ
serotyp
although
differ
bind
affin
note
report
overal
bound
factor
x
highest
affin
weak
bind
detect
factor
x
bind
chimer
vector
describ
previous
significantli
reduc
bind
vector
hexon
mutat
transgen
express
liver
also
dramat
decreas
follow
intraven
administr
either
vector
mice
preinject
mice
snake
venomderiv
protein
xbp
block
factor
x
bind
also
prevent
express
transgen
liver
paradigm
simultan
evad
ad
immun
gener
robust
diseasespecif
immun
respons
base
upon
substitut
highli
antigen
adspecif
epitop
capsid
protein
vaccinespecif
antigen
epitop
capsidmodifi
ad
vector
provid
vaccin
antigen
compon
capsid
rather
transgen
incorpor
immunogen
peptid
ad
capsid
offer
potenti
advantag
hypothet
exogen
protein
sourc
oppos
endogen
sourc
antigen
provid
transgen
express
process
hexonincorpor
antigen
result
humor
respons
akin
respons
provok
nativ
ad
capsid
protein
studi
design
determin
ideal
immunogen
capsid
locat
epitop
insert
kraus
colleagu
analyz
respons
induc
mice
vaccin
ad
vector
modifi
antigen
epitop
insert
differ
capsid
protein
somewhat
surprisingli
insert
influenza
ha
fiber
knob
induc
strongest
cellular
humor
immun
antigen
comparison
vaccin
vector
incorpor
antigen
hexon
penton
base
pix
howev
may
also
influenc
size
exact
locat
insert
note
immunodomin
epitop
recogn
ad
nab
found
highli
abund
hexon
protein
specif
surfaceexpos
hvr
loop
hexon
modif
prevent
ad
bind
coagul
factor
worgal
et
al
advanc
approach
develop
vaccin
vector
express
pseudomona
aeruginosa
epitop
hexon
region
vaccin
effect
p
aeruginosa
challeng
mice
repeat
administr
vaccin
enhanc
humor
cellular
respons
p
aeruginosa
epitop
although
specif
investig
mice
ad
pei
recent
group
advanc
paradigm
defin
rang
site
within
hexon
platform
present
antigen
epitop
peptid
motif
permit
assembl
viabl
capsidmodifi
vector
data
illustr
rang
antigen
epitop
insert
hexon
hvr
demonstr
greater
permiss
rang
insert
still
allow
product
viabl
ad
virion
result
also
indic
vaccin
ad
vector
contain
antigen
peptid
epitop
incorpor
within
capsid
hexon
absenc
encod
transgen
product
express
induc
signific
humor
respons
epitop
like
addit
capsid
locat
antigen
insert
effici
antigen
process
would
highli
depend
natur
peptid
sequenc
chosen
whether
capsidmodifi
ad
aid
vaccin
boost
focus
enhanc
immun
respons
incorpor
antigen
current
investig
given
recent
inform
regard
factor
x
bind
hexon
region
strategi
may
particularli
use
instanc
liver
untarget
requir
summari
studi
suggest
capsidincorpor
antigen
approach
may
offer
highli
effect
versatil
vaccin
strategi
could
also
impart
protect
ad
pei
howev
studi
kalyuzhini
et
al
also
point
previous
unobserv
role
hexon
intracellular
traffick
ad
vector
necessari
optim
transduct
cell
type
thu
care
consider
given
hexon
modif
depend
ident
cell
target
gutless
helperdepend
ad
hdad
vector
devoid
ad
gene
consist
ad
packag
invert
termin
repeat
sequenc
vector
specif
develop
mean
avoid
cellular
immun
ad
viral
gene
diminish
liver
toxic
thu
promot
longterm
transgen
express
howev
hdad
vector
still
suscept
vectorspecif
nab
induc
dosedepend
toxic
observ
nonhuman
primat
follow
system
administr
hdad
indic
antiad
respons
plagu
use
unmodifi
ad
vector
would
also
limit
util
hdad
vector
studi
indic
hdad
vector
deliv
system
induc
earli
capsiddepend
inflammatori
cytokin
similar
induc
vector
although
induc
cytokin
releas
shortliv
comparison
adapt
immun
respons
induc
discoveri
major
antiad
immun
respons
produc
capsid
protein
emphas
similar
unmodifi
ad
vector
system
deliv
hdad
vector
must
evad
capsidspecif
pei
provid
optim
efficaci
human
multipl
biochem
method
mask
ad
epitop
also
investig
includ
use
sodium
algin
polyhydroxypropyl
methacrylamid
activ
polyethylen
glycol
peg
polym
modif
protein
virus
peg
polym
refer
pegyl
improv
water
solubl
nontox
nonimmunogen
mask
ad
epitop
earli
report
show
pegyl
inhibit
recognit
nab
cell
decreas
induct
inflammatori
cytokin
enhanc
storag
stabil
well
pegyl
also
block
carmedi
transduct
cell
may
reduc
vector
uptak
hepatocyt
diminish
toxic
furthermor
peg
molecul
modifi
retarget
vector
bind
altern
cell
typespecif
molecul
transduct
egf
receptor
fgf
receptor
eselectin
integrin
howev
report
vari
whether
transgen
product
express
level
transgen
productspecif
immun
respons
reduc
vector
pegyl
regard
ensur
major
capsid
protein
attach
peg
polym
may
enhanc
transgen
product
express
follow
system
vector
inject
size
peg
modif
appear
critic
optim
transgen
product
express
well
evas
pei
appar
differ
molecular
weight
peg
polym
use
mask
vector
may
account
varianc
report
immun
protect
car
interact
transgeneproduct
express
vector
modif
small
peg
polym
kda
size
may
confer
immun
protect
larger
polym
kda
appear
requir
fulli
prevent
carintegrinmedi
transduct
liver
transgeneproduct
express
modifi
vector
mice
studi
also
corrobor
previous
publish
result
show
pegyl
vector
produc
significantli
lower
immun
respons
encod
antigen
although
may
also
influenc
rout
vector
administr
discuss
howev
presenc
pei
vector
modifi
peg
polym
least
kda
induc
significantli
greater
transgen
productspecif
immun
respons
interestingli
weaver
barri
report
modif
vector
peg
polym
prevent
gener
nab
follow
system
inject
studi
specif
evalu
effect
develop
cell
indic
pegyl
largermolecularweight
polym
consid
maxim
transgen
deliveri
induct
transgen
productspecif
cellular
humor
immun
respons
addit
examin
hofherr
et
al
suggest
pegyl
vector
kda
still
interact
blood
factor
ix
x
therebi
capabl
transduc
liver
cell
cultur
low
level
thu
import
determin
whether
low
level
liver
cell
transduct
also
observ
vivo
pegyl
vector
may
also
prove
benefici
primeboost
strategi
systemat
investig
weaver
barri
found
unmodifi
use
prime
boost
intramuscular
inject
naiv
anim
boost
respons
antigenspecif
antibodi
level
observ
howev
pegyl
use
prime
boost
antigenspecif
antibodi
level
boost
increas
low
level
primeinduc
antibodi
level
attain
unmodifi
therefor
nab
detect
studi
follow
immun
pegyl
vector
induc
pei
significantli
block
abil
boost
transgen
productspecif
humor
respons
suggest
multipl
boost
may
administ
howev
transgen
productspecif
cellular
respons
blunt
homolog
heterolog
pegyl
vector
respect
peg
polym
modif
use
induc
pei
thu
pegyl
differ
size
polym
may
prove
advantag
broaden
vector
repertoir
util
primeboost
scheme
presenc
ad
pei
need
corrobor
studi
nonhuman
primat
ultim
clinic
trial
coval
modif
retarget
ad
vector
also
achiev
poli
n
methacrylamid
hpma
react
amin
group
viru
surfac
hpma
coat
also
nontox
nonimmunogen
coat
hpma
prevent
vector
bind
car
subsequ
cell
entri
target
ligand
egf
fgf
vegf
incorpor
polym
coat
facilit
vector
uptak
transgen
product
express
target
cell
inclus
reduct
degrad
disulfid
bond
facilit
intracellular
uncoat
hpma
polym
allow
product
infect
recent
report
also
indic
increas
polym
concentr
ad
surfac
mgml
prevent
vector
transduct
carposit
cell
time
transgen
product
express
affect
hpma
coat
addit
nab
recogn
hpmacoat
vector
allow
effici
transgen
product
express
vitro
hpmacoat
vector
increas
plasma
halflif
mice
associ
human
erythrocyt
significantli
decreas
vitro
allow
transduct
cell
transgeneproduct
express
presenc
human
erythrocyt
interestingli
nonspecif
target
liver
dramat
decreas
fgftarget
hpmacoat
administ
intraven
mice
carlisl
et
al
recent
demonstr
coat
ad
vector
newli
design
hpma
polym
also
prevent
factor
xbind
unlik
pegyl
therefor
hpma
coat
appear
provid
shield
ad
vector
innat
adapt
arm
immun
system
howev
full
potenti
polym
yet
examin
anim
model
ad
pei
particular
effect
hpma
coat
regard
tcell
respons
ad
vector
protein
transgen
product
investig
although
factor
xbind
hexon
block
hexon
epitop
still
present
cell
addit
efficaci
adbas
vaccin
reli
least
part
direct
uptak
dc
may
facilit
adantibodi
immun
complex
intern
fcreceptor
fcr
interact
combin
technolog
merg
hpma
coat
addit
target
ligand
may
import
facilit
enhanc
induct
ad
vaccinespecif
respons
target
dc
would
obviou
next
step
altern
target
cell
via
egf
vegf
may
allow
target
cell
becom
substanti
antigen
product
factori
produc
antigen
secret
protein
apoptot
bodi
may
abli
endocytos
dc
effect
induct
cell
via
crossprim
cell
effect
way
express
antigen
gene
achiev
greatest
magnitud
appropri
qualiti
type
respons
complet
known
probabl
requir
extens
investig
respect
individu
antigen
diseas
altern
strategi
shield
ad
pei
includ
util
bispecif
adapt
bind
ad
capsid
protein
chang
cellspecif
ad
transduct
bispecif
adapt
origin
develop
mean
block
carmedi
transduct
retarget
ad
uniqu
cell
surfac
receptor
one
bispecif
adapt
shown
promis
mediat
transduct
normal
refractori
dc
consist
solubl
domain
car
fuse
ectodomain
bind
simultan
lead
ad
transduct
activ
dc
induc
potent
antigenspecif
immun
respons
vitro
effici
dc
transduct
observ
presenc
nab
collect
human
patient
report
also
indic
induct
antigenspecif
immun
respons
follow
adaptermedi
vector
deliveri
studi
demonstr
signific
progress
made
toward
modifi
ad
vector
success
evad
ad
pei
subsequ
toxic
also
highlight
need
analysi
ensur
adequ
therapeut
immun
respons
gener
interestingli
rout
vector
administr
may
signific
impact
immun
respons
gener
ad
vector
includ
polymerco
vector
ad
success
infect
human
via
mucos
rout
stand
reason
immun
via
natur
rout
transmiss
allow
circumvent
immun
inde
report
shown
mucos
administr
ad
vector
promot
develop
antiad
immun
allow
induct
transgen
productspecif
immun
respons
may
due
least
part
lower
level
nab
local
human
mucosa
compar
system
circul
importantli
system
mucos
immun
adencod
transgen
product
trigger
mucos
vaccin
provid
protect
pathogen
infect
administ
prophylact
even
presenc
ad
pei
sever
laboratori
continu
investig
benefit
may
result
administr
vector
variou
rout
whether
combin
biochem
modif
reduc
immun
toxic
anticip
intranas
deliveri
unmodifi
vector
naiv
mice
lead
transgen
express
predominantli
nose
lung
local
express
minim
exposur
humor
cellular
reactiv
minim
chanc
liver
toxic
howev
administ
intranas
modif
peg
polym
least
kda
appear
necessari
induc
transgen
express
antigenspecif
antibodi
level
similar
induc
unmodifi
attach
addit
glucos
galactos
ligand
peg
moieti
increas
transgen
express
follow
intranas
administr
intramuscular
inject
sugar
ligand
pegyl
vector
may
enhanc
vector
stabil
abil
target
carbohydratespecif
receptor
antigenpres
cell
apc
interestingli
follow
intranas
administr
naiv
mice
lowest
level
nab
observ
mice
vaccin
peg
modifi
vector
vector
modifi
larger
peg
polym
induc
level
nab
similar
unmodifi
clear
whether
pei
would
alter
select
inhibit
adhumor
respons
intranas
administr
pegmodifi
vector
specif
evalu
effect
administr
rout
well
impact
vectorspecif
pei
examin
respect
gener
antigenspecif
tcell
respons
two
differ
transgen
product
naiv
mice
intramuscular
administr
vector
without
peg
modif
kda
produc
level
green
fluoresc
protein
gfp
specif
cell
howev
intranas
administr
produc
half
number
gfpspecif
cell
within
group
pegmodifi
vector
significantli
increas
respons
interestingli
peg
modif
produc
differ
effect
tcell
respons
made
vectordeliv
gag
antigen
intramuscular
administr
produc
higher
respons
compar
gener
intranas
administr
pegyl
kda
inhibit
magnitud
tcell
respons
case
reduc
transduct
effici
pegyl
may
affect
outcom
contrast
gfpspecif
respons
gener
intranas
administr
gagspecif
tcell
respons
increas
pegyl
vector
differ
may
reflect
differ
time
administr
vector
measur
tcell
respons
week
gfp
week
gag
altern
immunogen
encod
antigen
may
differ
accordingli
influenc
tcell
respons
eg
gfp
known
weak
antigen
rel
gag
respect
gener
cellular
respons
mice
pei
pegyl
vector
induc
gagspecif
tcell
respons
similar
mice
follow
intramuscular
administr
also
interest
pegyl
vectorspecif
pei
partial
diminish
capac
vaccin
homolog
modifi
vector
impact
unmodifi
pegyl
vaccin
sugarmodifi
pegyl
vector
would
interest
investig
scenario
well
especi
light
enhanc
transgen
express
observ
follow
administr
vector
thu
abil
shield
pei
modif
highmolecularweight
peg
polym
may
depend
rout
vector
administr
encod
antigen
influenc
magnitud
qualiti
result
cellular
humor
respons
use
mous
model
ebola
croyl
et
al
investig
differ
immun
respons
surviv
infecti
pathogen
challeng
follow
immun
system
intramuscular
mucos
intranas
per
oral
administr
vector
encod
ebola
zair
glycoprotein
antigen
mice
pei
transgen
productspecif
antibodi
produc
vector
administ
intranas
naiv
mice
intramuscular
inject
vector
result
higher
antigenspecif
tcell
respons
intranas
per
oral
rout
administr
howev
pei
dramat
reduc
tcell
respons
gener
intramuscular
inject
vector
intranas
per
oral
vector
administr
effect
intranas
administr
tcell
respons
induc
unmodifi
ad
vector
similar
observ
weaver
barri
discuss
previous
critic
test
vector
efficaci
intranas
administr
fulli
protect
mice
pei
lethal
challeng
mouseadapt
ebola
hypothes
pegyl
may
afford
addit
vector
protect
pei
group
also
investig
whether
pegyl
administ
oral
could
improv
immun
respons
surviv
ebola
challeng
although
pegyl
facilit
product
antigenspecif
antibodi
mice
pei
cell
detect
vaccin
mice
surviv
ebola
challeng
light
studi
review
previou
section
would
interest
investig
whether
modifi
ad
vector
variou
size
peg
polym
provid
addit
benefit
oral
administ
vector
studi
clearli
point
potenti
mucos
vector
deliveri
intranas
administr
particular
evad
ad
pei
howev
concern
rais
intranas
administr
follow
earli
studi
report
detect
transgen
product
express
olfactori
bulb
support
report
transgen
product
express
mous
brain
follow
intranas
administr
vector
observ
huang
et
al
transduct
appear
carmedi
sinc
modif
retarget
adapt
protein
significantli
decreas
transgen
express
howev
damjanov
et
al
found
littl
evid
ad
vector
distribut
brain
follow
intranas
administr
threefold
lower
vector
dose
speci
togeth
report
indic
intranas
administr
ad
vector
may
evad
ad
pei
induc
power
immun
encod
antigen
vector
dose
may
critic
consider
one
popular
method
immunotherapi
involv
ex
vivo
transduct
dc
vector
follow
cytokineinduc
matur
cultur
transduc
dc
readminist
vaccin
evalu
clinic
trial
cancer
patient
method
lead
antigenspecif
immun
respons
approxim
patient
cancer
regress
achiev
approxim
patient
sever
hypothes
put
forward
explan
effect
ad
pei
recent
examin
mice
vaccin
dc
transduc
vector
encod
hepat
c
protein
pei
effect
result
antihepat
c
immun
respons
addit
nab
gener
method
thu
vaccin
cell
transduc
vector
ex
vivo
may
provid
effect
mean
avoid
ad
pei
howev
harvest
ex
vivo
manipul
dc
technic
well
biolog
relat
issu
need
address
vaccin
transduc
cell
becom
standard
previous
mention
ad
vector
util
wide
rang
vaccin
approach
howev
recent
find
step
hiv
vaccin
clinic
trial
fail
reproduc
promis
find
observ
anim
model
system
regard
vaccin
use
vector
fail
protect
individu
infect
associ
enhanc
infect
vaccin
recipi
ad
pei
howev
lack
protect
altogeth
surpris
given
previou
result
macaqu
demonstr
similar
primeboost
strategi
vector
encod
siv
antigen
control
viral
replic
result
led
varieti
specul
explan
particular
recent
studi
point
critic
role
crossreact
cell
limit
efficaci
vaccin
deriv
human
nonhuman
tropic
ad
howev
studi
anim
model
date
focus
evad
ad
pei
context
nab
overal
find
emphas
need
strategi
reduc
vector
immunogen
respect
evad
recognit
preimmun
sera
cell
individu
ad
pei
well
avoid
induct
new
adspecif
respons
vaccin
recipi
without
pei
two
accomplish
necessari
preserv
adbas
vector
premier
vector
vaccin
develop
futur
evalu
also
focu
effect
dc
transduct
immunogen
exampl
fcrmediat
uptak
ad
vector
dc
may
lead
enhanc
transduct
activ
innat
adapt
respons
polym
coat
may
impair
uptak
adjuv
activ
vector
deriv
altern
speciestrop
ad
uniqu
dcspecif
effect
induc
effect
dc
activ
behav
manner
similar
human
subgroup
c
ad
includ
nonhuman
primat
ad
subgroup
b
includ
e
includ
strongli
stimul
pdc
produc
high
level
inflammatori
cytokin
immedi
earli
respons
pdc
may
profoundli
contribut
suscept
threshold
patient
may
vector
toxic
thu
vector
subtyp
uniqu
immunestimulatori
properti
need
consid
design
adbas
therapeut
vaccin
strategi
anoth
potenti
concern
regard
adbas
vaccin
highlight
recent
involv
capac
ad
integr
cellular
genom
long
thought
ad
genom
integr
occur
extrem
ineffici
rate
therebi
provid
safeti
advantag
viru
patient
vaccin
howev
recent
report
indic
ad
randomli
integr
genom
cell
cultur
vitro
much
higher
rate
origin
believ
may
relat
rate
cell
divis
thu
light
potenti
side
effect
random
integr
cell
transform
observ
retrovirus
adbas
vaccin
may
requir
care
monitor
regard
previous
expect
hand
studi
mice
ertl
laboratori
suggest
persist
transcript
activ
ad
transgen
may
prove
advantag
properti
although
exact
mechan
underli
persist
follow
ad
vector
vaccin
determin
shown
provid
suffici
low
level
transgen
product
express
act
sourc
homeostat
signal
maintain
pool
longterm
antigenspecif
effector
memori
cell
effector
memori
cell
could
mount
fast
lytic
respons
antigenbear
cell
potenti
provid
enhanc
vaccin
protect
addit
shield
retarget
vector
improv
anim
model
need
studi
ad
pei
mechan
provid
relev
preclin
inform
observ
croyl
et
al
nab
induc
mous
model
via
intramuscular
inject
ad
may
adequ
repres
level
observ
human
mucos
region
follow
natur
exposur
inhal
discoveri
car
express
human
rat
erythrocyt
nonhuman
primat
mous
rabbit
dog
erythrocyt
yet
anoth
exampl
crucial
differ
human
anim
must
address
inde
even
immun
respons
nonhuman
primat
must
evalu
preclin
result
properli
interpret
regard
human
clinic
translat
longterm
efficaci
studi
examin
durat
protect
afford
vaccin
must
also
undertaken
rout
vector
administr
obvious
affect
therapeut
outcom
method
administ
therapeut
vector
mucos
less
wellexplor
rout
topic
may
provid
promis
new
avenu
explor
topic
administr
would
less
suscept
neutral
humor
cellular
respons
ad
site
insul
system
exposur
past
year
brought
excit
technic
advanc
along
critic
import
inform
elucid
immun
mechan
respons
toxic
poor
therapeut
outcom
respons
ad
vectorbas
therapeut
presenc
ad
pei
studi
reveal
complex
factor
influenc
efficaci
adbas
vaccin
emphas
stringent
condit
potenti
adbas
therapi
must
evalu
thu
research
next
year
undoubtedli
focu
two
area
fulli
character
compon
pei
adopson
nab
memori
cell
latent
ad
infect
affect
efficaci
ad
vectorbas
vaccin
continu
explor
new
technic
advanc
promot
evas
humor
cellular
recognit
ad
vector
pei
reduc
induct
specif
ad
immun
maintain
enhanc
immunogen
toward
deliv
transgen
vaccin
product
respect
expand
util
gutless
ad
vector
may
continu
promis
advanc
also
becom
evid
mani
factor
must
evalu
optim
specif
vaccin
care
consider
must
given
determin
uniqu
primeboost
combin
chosen
vector
subgroup
strain
vector
modif
polym
coat
epitopecapsid
incorpor
transgen
select
vector
dose
administr
rout
provid
optim
therapeut
outcom
treat
immun
uniqu
diseas
interest
patient
ad
pei
inde
rout
vector
administr
avoid
exposur
immun
recognit
transduct
epitheli
layer
cell
mucosa
cutan
tissu
appear
promis
rout
explor
allow
realiz
full
potenti
ad
vectorbas
vaccin
final
recent
understand
profound
differ
speciesspecif
ad
properti
patholog
among
nonhuman
primat
mice
human
imper
anim
model
close
mimic
human
biolog
patholog
ad
infect
develop
fulli
defin
model
invalu
investig
relev
properti
ad
vector
mechan
elicit
immun
respons
promot
immun
evas
vector
closer
accur
predict
therapeut
outcom
vaccin
trial
human
acut
toxic
innat
immun
respons
occur
presenc
absenc
preexist
immun
adenoviru
ad
hinder
util
adbas
vector
human
gene
therapi
current
avail
preclin
anim
model
accur
recapitul
human
immun
respons
ad
vector
temporari
administr
immunosuppress
drug
well
vector
modif
includ
biochem
modif
genet
modif
altern
chimer
serotyp
rout
administr
cell
deliveri
vehicl
investig
method
protect
ad
vector
preexist
immun
reduc
vector
immunogen
uniqu
combin
multipl
immun
evas
techniqu
like
requir
develop
optim
strategi
ad
vectorbas
approach
use
therapeut
effect
protect
treat
specif
diseas
must
care
evalu
stringent
anim
model
